Exai Bio, a next-generation oncRNA- and generative AI-based liquid biopsy company, today announced a peer-reviewed publication about its generative AI model in Nature Communications. The paper ...
Biofidelity, a leader in innovative genomic solutions, today announced the launch of Aspyre Clinical Test for Lung for liquid biopsy samples. Aspyre Clinical Test for Lung analyzes all ...
Global Metastatic Colorectal Cancer Market to Record Stellar Growth with Advancements in Treatments and Rise in Healthcare InfrastructuresRockville, MD, Nov. 20, 2024 (GLOBE NEWSWIRE) -- According to ...
Lung toxicity and fibrosis are caused by inhaling particles, pathogens, and therapeutics. They can also occur following ...
The FDA has approved FoundationOne Liquid CDx as a companion diagnostic for patients with metastatic non–small cell lung ...
Lung cancer treatment has witnessed a revolution in recent years, largely driven by the increasing understanding of genetics ...
FoundationOne Liquid CDx is now FDA-approved to identify mNSCLC patients with MET exon 14 skipping alterations for tepotinib ...
The Guildford, England-based liquid biopsy company is presenting the new test results at the American Association for Cancer Research's Special Conference, 'Liquid Biopsy: From Discovery to Clinical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback